Sugi Predict

Sugi Predict / Compounds / SCHEMBL2239446

SCHEMBL2239446

SCHEMBL2239446

CC(C)(C)OC(=O)N1CCC2CNCC2C1

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 7/20 0.51
▸ CHRNB4 P30926 7/20 0.51
▸ CHRNA3 P32297 7/20 0.51
▸ CHRNA4 P43681 7/20 0.51
▸ GPR119 Q8TDV5 5/20 0.48
▸ NR1H2 P55055 1/20 0.48
▸ HPGD P15428 1/20 0.47
▸ JAK2 O60674 1/20 0.46
▸ JAK1 P23458 1/20 0.46
▸ CHRNA7 P36544 5/20 0.45
▸ RECQL P46063 1/20 0.44
▸ EPHX1 P07099 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25154183 1.00 CHRNB2 (0.51) CHRNB2CHRNB4CHRNA3CHRNA4GPR119
SCHEMBL4516507 1.00 CHRNB2 (0.51) CHRNB2CHRNB4CHRNA3CHRNA4GPR119
SCHEMBL26116742 0.94 GPR119 (0.48) CHRNB2CHRNB4CHRNA3CHRNA4GPR119
SCHEMBL2881371 0.92 GPR119 (0.55) GPR119HPGDRECQLEPHX1
SCHEMBL2881367 0.92 GPR119 (0.55) GPR119HPGDRECQLEPHX1
SCHEMBL3784890 0.92 GPR119 (0.55) GPR119HPGDRECQLEPHX1
SCHEMBL16144654 0.91 MEN1 (0.50) CHRNB2CHRNB4CHRNA3CHRNA4NR1H2
SCHEMBL14971262 0.90 GPR119 (0.48) CHRNB2CHRNB4CHRNA3CHRNA4GPR119
SCHEMBL24364944 0.90 GPR119 (0.48) CHRNB2CHRNB4CHRNA3CHRNA4GPR119
SCHEMBL26543757 0.90 GPR119 (0.45) GPR119NR1H2HPGDJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114667145-A Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders 拜尔哈文制药股份有限公司 2022-06-24 — — CN claimed
US-12551478-B2 Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) 2026-02-17 — — US disclosed
WO-2025242908-A2 NOVEL COMPOUNDS GENOME THERAPEUTICS LTD (GB) 2025-11-27 — — WO disclosed
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-09-04 — — US disclosed
US-20250206732-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS ARVINAS OPERATIONS, INC. 2025-06-26 — — US disclosed
EP-4536650-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 — — EP disclosed
WO-2025039676-A1 PAN-KRAS PROTEIN TARGETED DEGRADER COMPOUND AND USE THEREOF 贝达药业股份有限公司 2025-02-27 — — WO disclosed
WO-2024249950-A1 FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN BIOMEA FUSION, INC. (US) 2024-12-05 — — WO disclosed
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2024-08-29 — — US disclosed
US-12049466-B2 Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-30 — — US disclosed
US-20060183762-A1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS ZOETIS WLC LLC 2006-08-17 — — US disclosed
EP-1401830-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS Warner-Lambert Company LLC (US) 2004-03-31 — — EP disclosed
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance WARNER-LAMBERT COMPANY 2003-06-19 — — US disclosed
WO-2002102793-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2002-12-27 — — WO disclosed
EP-1255739-A1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 2002-11-13 — — EP disclosed
WO-2001053273-A1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 2001-07-26 — — WO disclosed
US-5726182-A TREATMENT OF BACTERIAL INFECTIONS ABBOTT LABORATORIES (US) 1998-03-10 — — US disclosed
US-5599816-A BACTERICIDE ABBOTT LABORATORIES (US) 1997-02-04 — — US disclosed
US-5580872-A ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS ABBOTT LABORATORIES (US) 1996-12-03 — — US disclosed
EP-0723545-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1996-07-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12551478-B2 Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity IDO2, IDO1, HDAC2 CHRNB2 769/4885CHRNB4 1246/4885CHRNA3 564/4885
US-20060183762-A1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS ABL1, NQO2, CBR3 CHRNB2 3372/4885CHRNB4 3776/4885CHRNA3 2972/4885
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR CHRNB2 4753/4885CHRNB4 4719/4885CHRNA3 4799/4885
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance ABCC1, RPS6KA1, SIGMAR1 CHRNB2 4790/4885CHRNB4 4753/4885CHRNA3 4092/4885
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR CHRNB2 4753/4885CHRNB4 4719/4885CHRNA3 4799/4885
US-20250206732-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS KRAS, MDM2, VHL CHRNB2 4585/4885CHRNB4 4690/4885CHRNA3 4836/4885
US-12049466-B2 Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors USP30, UCHL1, ADRM1 CHRNB2 2313/4885CHRNB4 2851/4885CHRNA3 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.